For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
What Trump’s vaccine executive order actually does
Yesterday, President Trump signed an executive order directing federal health agencies to revise childhood vaccine recommendations, reducing the number of vaccines recommended for…
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Search Posts
Blog
Moment of truth: Reassessing Obamacare enrollment predictions
In 2025, several organizations predicted Obamacare enrollment in a world without the ACA’s expanded subsidies. That world became reality this year. Some groups’ predictions…
Blog
Six takeaways from the recent Obamacare announcements
Every year, health insurers participating in the Exchanges (Obamacare) must announce their planned premium increases for the following year well in advance, so federal…
Blog
The free market case for AI chatbots in mental health care
Concerns that new technologies may cause negative psychosocial effects are part of a growing public conversation. Questions regarding the intersection between the digital world…
Blog
The fraud problem hidden in the subsidy debate
Last fall, critics argued that under the Republican budget plan, 22.4 million people would see their Obamacare subsidies reduced to prepandemic levels. As Jeremy…
News Release
FDA commissioner resignation opens opportunity for refocus on science over politics
After a somewhat tumultuous tenure, FDA commissioner Marty Makary is stepping down. While Dr. Makary made his mission to accelerate drug approval and bring…
Blog
Don’t hinder biosimilar development
In its most recent legislative session, the Florida legislature considered precluding pharmacy benefit managers (PBMs) from holding an investment interest in biosimilar manufacturing.